our evidence-based approach
The science behind early allergen introduction
10+ years of research demonstrates that early, consistent exposure to allergenic foods supports immune tolerance. Amuse brings this science to families in just three drops a day.
Physician-Developed
Research-Backed
3rd Party Tested
Organic Ingredients
Physician-Developed
Research-Backed
3rd Party Tested
Organic Ingredients
10+ years of research demonstrates that early, consistent exposure to allergenic foods supports immune tolerance. Amuse brings this science to families with a novel sublingual delivery method.
The Growing Allergy Epidemic
1 in 13
Children have food allergies
142%
Increase since 1995
5.6M
Children affected in the US
+300%
More ER visits since 2008
Food allergies have more than doubled in the past 30 years, affecting millions of children and families
Source: Epidemiology and Burden of Food Allergy. Warren CM, Jiang J, Gupta RS., Current Allergy and Asthma Reports. 2020;20(2):6. doi:10.1007/s11882-020-0898-7.
25 Years of Evolving Science
From avoidance to early introduction: How research transformed our understanding
previous guidance
2000
Avoidance Recommended
The AAP, AAAAI, and ACAAI recommended avoiding peanut and egg for babies under 1 year, especially in high-risk families. This well-intentioned guidance was based on the assumption that delayed exposure would prevent sensitization.
Result: Sharp increases in peanut and egg allergies over the following decade, suggesting avoidance does not affect sensitization
Policy Reversal
2008
Guidelines Retracted
Recognizing that allergy rates continued to climb despite avoidance recommendations, major medical organizations retracted their guidance. This opened the door for new research into early introduction.
Result: Sharp increases in peanut and egg allergies over the following decade, suggesting avoidance does not affect sensitization
Breakthrough
2015
LEAP Study Published
The landmark Learning Early About Peanut (LEAP) allergy study revolutionized the field by demonstrating that early peanut introduction dramatically reduced allergy development in high-risk infants.
Findings: 86% reduction in peanut allergy among high-risk infants who consumed peanut regularly from 4-11 months
Confirmation
2016
EAT Study Published
The Enquiring About Tolerance (EAT) study extended findings to the general population and multiple allergens, showing that early introduction of six allergenic foods reduced food allergy prevalence.
Findings: 67% reduction in egg allergy and 100% prevention of peanut allergy in the early introduction group with good adherence
New Guidelines
2017
Updated Recommendations
Based on compelling evidence, the AAP, AAAAI, and ACAAI issued new guidelines recommending early allergen introduction for all infants, including those at high risk, starting around 4-6 months.
Innovation
2026
Amuse Launches
While guidelines exist, practical implementation remains a challenge for families. Amuse bridges this gap with novel sublingual delivery that enables even earlier introduction (from 2 months) and eliminates barriers like prep and planning.
Our patent-pending formulation allows safe allergen exposure before babies can eat solid foods, capturing the critical 2-6 month immune development window.
Landmark Clinical Studies
2015
LEAP Study
Learning Early About Peanut Allergy
Through a randomized study, 640 high-risk infants either consumed or avoided peanut from 4-11 months and were then tested for peanut allergy at 5 years.
key finding
86%
Reduction in peanut allergy among high-risk infants who consumed peanut early vs. those who avoided it
2016
EAT Study
Enquiring About Tolerance
EAT tested early introduction of 6 allergenic foods (peanut, egg, milk, sesame, whitefish, wheat) in standard-risk infants from 3 months.
key finding
67%
Reduction in egg allergy and prevention of any peanut allergy in early introduction group with good adherence
PreventADALL
Preventing Atopic Dermatitis and Allergies
A Norwegian study testing early introduction of peanut, milk, wheat, and egg from 3 months in over 2,000 infants.
key finding
48%
Lower rate of food allergy at 3 years in early introduction group, with strongest effect for egg allergy
Three pivotal trials that transformed food allergy prevention
The Evidence is Clear
Across different populations, multiple allergens, and various study designs, the conclusion is consistent: early introduction of allergenic foods significantly supports immune tolerance and may help reduce the risk of food allergies.
Enquiring About Tolerance (EAT) Study: Feasibility of an Early Allergenic Food Introduction Regimen. Perkin MR, Logan K, Marrs T, et al. The Journal of Allergy and Clinical Immunology. 2016;137(5):1477-1486.e8. doi:10.1016/j.jaci.2015.12.1322.
Skin Emollient and Early Complementary Feeding to Prevent Infant Atopic Dermatitis (PreventADALL): A Factorial, Multicentre, Cluster-Randomised Trial. Skjerven HO, Rehbinder EM, Vettukattil R, et al. Lancet (London, England). 2020;395(10228):951-961. doi:10.1016/S0140-6736(19)32983-6.
The Critical Window
Why timing matters for immune development
Sensitization Begins Earlier Than You Think
Research shows that up to 20% of infants may already be sensitized to common allergens by 4–6 months—before they typically start solid foods. This early sensitization window makes Amuse’s approach particularly valuable.
Infant Sensitization Rates by Age
7%
3 MONTHS
36%
4 MONTHS
40%
1 YEAR
Early regular egg exposure in infants with eczema: A randomized controlled trial. Palmer DJ, Prescott SL, et al. J Allergy Clin Immunol. 2013 Aug;132(2):387-92.e1. doi: 10.1016/j.jaci.2013.05.002.
Sensitization to Food and Inhalant Allergens in Relation to Atopic Diseases in Early Childhood: A Birth Cohort Study.Chiu CY, Huang YL, Tsai MH, et al.PloS One. 2014;9(7):e102809. doi:10.1371/journal.pone.0102809.
Diverse Age-Incidence Patterns of Atopic Sensitization in an Unselected Finnish Population Up to 12 Years. Pyrhönen K, Kulmala P, Näyhä S, Läärä E. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology. 2019;122(5):522-531.e3. doi:10.1016/j.anai.2019.02.027.
Sensitization Begins Earlier Than You Think
Research shows that up to 17% of infants may already be sensitized to common allergens by 6 months—before they typically start solid foods. This early sensitization window makes Amuse’s approach particularly valuable.
Infant Sensitization Rates by Age
7%
3 MONTHS
17%
6 MONTHS
21%
1 YEAR
Tedner et al. Allergy. 2021;76(9):2730–2739 and references therein
Why 2 to 6 Months Matters
This is the optimal window for immune system education. The infant immune system is developing oral tolerance mechanisms, making it most receptive to learning which proteins are safe.
Why Drops Make the Difference
Whole peanuts and eggs aren’t safe for babies under 6 months. Amuse drops make early allergen introduction possible right when it matters most.
The Science of Sublingual Delivery
Why the route of exposure matters for immune tolerance
Direct Immune System Engagement
The sublingual mucosa (tissue under the tongue) is rich in specialized immune cells called dendritic cells. These cells capture allergen proteins and present them to the immune system in a way that promotes tolerance rather than allergic responses.
1
Targeted Delivery: Sublingual administration directly exposes oral mucosal immune cells to allergen proteins, initiating tolerance-promoting pathways.
2
Earlier Start: Safe for infants as young as 2 months, before they can safely consume whole allergenic foods, capturing the critical immune development window.
3
Consistent Dosing: Precise microdosing ensures reliable, repeated exposure without the variability of food-based introduction methods.
4
Enhanced Safety: Microdoses well below reaction thresholds minimize risk while still providing effective immune system exposure.
Clinical Note: Sublingual immunotherapy (SLIT) has been used safely and effectively for treating environmental and food allergies for decades. Amuse adapts this established approach for preventive food allergen introduction.
Developed by an Allergist
Expertise you can trust for your baby’s health
Dr. Brynn Everist, MD
Board-Certified Allergist & Immunologist
Mayo Clinic Trained
Pediatric Specialist
15+ Years Experience
Dr. Everist founded Prairie Allergy and pioneered sublingual immunotherapy approaches for food allergies in her Kansas City practice. As both an allergist and a mother of three, she created Amuse to solve the gap between research-backed guidelines and practical family implementation. Her clinical expertise ensures Amuse is both scientifically sound and parent-friendly.
Science-Backed Solutions for
Modern Families
Join the parents supporting their babies’ immune wellness with research-driven early introduction